P M Terheggen

Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.

P M Terheggen, J Y Emondt, B.G.J. Floot et al. · PubMed · 1990 · 55 citations

Chemoprevention Strategy, Apoptosis, Molecular Biology +18

Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response.

F A Blommaert, Con Michael, P M Terheggen et al. · PubMed · 1993 · 53 citations

Tumor Biology, Carboplatin-induced Nuclear Stain, Cisplatin Administration +14

Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients.

P M Terheggen, R. Dijkman, Adrian C. Begg et al. · PubMed · 1988 · 48 citations

Platinum-treated Cancer Patients, Interaction Products, Oncology +13

A role for mast cells and the vasoactive amine serotonin in T cell-dependent immunity to tumors.

Henk Van Loveren, Willem Den Otter, Robin Meade et al. · The Journal of Immunology · 1985 · 43 citations · Full text

Mast Cell Disorder, Immunology, T Cell-dependent Immunity +17

Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): Tolerance and relation to leukocyte and buccal cell platinum-DNA adducts

Inderbir S. Gill, Franco M. Muggia, P M Terheggen et al. · Annals of Oncology · 1991 · 39 citations

Dose-escalation Study, Chromatin, Medicine +6